Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 311 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Overweight Subjects Clear all

Conditions: Pre-diabetes, Obese, Glucose Intolerance
Interventions: BCAA; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC0194-0499, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 22 Years to 55 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity
Interventions: lorcaserin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Willingboro, New Jersey

Conditions: Overweight and Obesity
Interventions: Epitomee Capsule; Device
Lead sponsor: Epitomee medical; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina • Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: MEDI0382, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions: Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabete Type 2, Obesity
Interventions: HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Overweight, Obese
Interventions: Placebo, EMIQ; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight, Obesity
Interventions: pramlintide acetate, metreleptin, placebo-P, placebo-M; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 33 more

Conditions: Obesity; Overweight
Interventions: ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg; Drug
Lead sponsor: Rose Pharma Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 3,731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 64 more

Conditions: Obesity & Overweight
Interventions: Redefine, Placebo; Dietary Supplement
Lead sponsor: Nature's Sunshine Products, Inc.; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Lehi, Utah

Conditions: Diabetes, Obesity
Interventions: EXERCISE; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Metabolic Syndrome
Interventions: 3-V Bioscience-2640; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 35 Years to 60 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Obesity, Diabetes
Interventions: home-delivered meals, diabetes education for 12 months; Dietary Supplement · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: exenatide 5 mcg, exenatide 10 mcg, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 20 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Anniston, Alabama • Anaheim, California • Lomita, California + 32 more

Conditions: Insulin Resistance
Interventions: (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose, Placebo; Drug · Other
Lead sponsor: EncuraGen, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity, Insulin Resistance
Interventions: Glucosamine Hydrochloride; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Lorcaserin hydrochloride; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Overweight and Obesity, Type2 Diabetes, NAFLD
Interventions: DD01, Placebo; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Chula Vista, California • Fort Myers, Florida • Orlando, Florida

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: HydraSolve T2D™; Device
Lead sponsor: Medality Medical; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 35
States / cities: Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more

Search by objective public record fields.

Investigation of an Amino Acid Supplement on Glucose Levels in Obese Subjects

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults

Brain Blood Flow and Lactate in Non-obese and Obese Subjects

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

Exeantide in Type 2 Diabetes on Insulin

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

Effects of Oral Glucosamine on Insulin and Blood Vessel Activity in Normal and Obese People

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes